

Evaluated outcomes in patients with chronic hepatitis C

Sara Ashtari¹, Mohsen Vahedi², Mohammad Amin Pourhoseingholi¹, Mohammad Reza Zali¹

¹Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

ABSTRACT

Aim: The objective of this study was to evaluate the real outcomes of chronic hepatitis C patients, who were treated with interferon plus ribavirin (INF-RBV) and peg-interferon plus ribavirin (PEG-RBV).

Background: Despite the PEG-RBV has become a standard treatment of hepatitis C virus (HCV) around the world; and in Iran too, but in developing countries like Iran, INF-RBV is still used among some patients for treating HCV, due to the high costs of treatment with PEG-RBV.

Patients and methods: The present cross-sectional study was conducted on 77 naïve patients referred to a private gastroenterology clinic between years 2007 through 2009 in Tehran. Patients had participated in this study taking two types of combination therapies, based on standard protocol of the Iranian Ministry of Health. At the end of the treatment, sustain virological response (SVR) rate was evaluated.

Results: The outcomes showed in INF-RBV treatment is 11.6%, 16.3% and 34.9% in patients who suffered from relapse, lost follow-up for treatment and non-responder, respectively, and finally 37.2% of the patients reached SVR. In PEG-RBV, treatment outcomes were as follows; 2.9%, 14.7% and 14.7% patients were non-responders, lost follow-up for treatment and suffered from a relapse, respectively, and 67.6% of the patients reached SVR. The multivariate-adjusted odds ratios of outcomes showed that treatment with PEG-RIB and also genotype 3a than the other genotypes in this treatment had more chance to achieve SVR.

Conclusion: The findings of the present study showed the rate of SVR in patients who treated with PEG-RBV significantly was higher than patients who were treated with INF-RBV. Also in PEG-RBV the chance of achieving SVR is higher among the patients with genotype 3a than among those with other genotypes.

Keywords: chronic hepatitis C, interferon, peg-interferon, sustain virological response.

(Please cite as: **Ashtari S, Vahedi M, Pourhoseingholi MA, Zali MR. Evaluated outcomes in patients with Chronic Hepatitis C. Gastroenterol Hepatol Bed Bench 2013;6(Suppl. 1): S58-S64.**)

Introduction

Hepatitis C virus (HCV) infection has a large prevalence worldwide (1-4). HCV is one of the most common causes of chronic liver disease, and the third leading cause of death in end-stage renal disease patients (5-8). The patients suffering from chronic HCV for an average of 15 years have 15% risk of developing cirrhosis and 1-5% risk of

developing hepatocellular carcinoma (HCC) (9, 10). The treatment regimen of chronic hepatitis C has changed significantly over the past decades around the world. In the mid-1990s, monotherapy with interferon administered by an injection 3 times weekly for 6 to 12 months was associated with an overall sustained virological response (SVR) of 6% to 10% (11-14). The addition of ribavirin to interferon (INF-RBV) in the late 1990s was associated with an increase in SVR to approximately 40-45% (15-17). Currently, the

Received: 21 June 2013 Accepted: 18 August 2013

Reprint or Correspondence: Sara Ashtari, MSc.

Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

E-mail: sara_ashtari@yahoo.com

combination of peg-interferon plus ribavirin (PEG-RBV) is the treatment for patients with chronic HCV infection (18-20). PEG-RBV has produced an overall SVR rates of up to 66% in HCV mono-infected patients (21-23), and 50% in patients with human immunodeficiency virus (HIV)-HCV co-infection (24, 25).

The objective of therapy is to eradicate the virus and prevent potential complications from CHC infection. The primary goal of treatment in chronic hepatitis C patients is to achieve an SVR, which is operationally defined as the absence of HCV RNA (detectable through PT-PCR) within six months of treatment termination (26). Achievement of SVR has been associated with improvement in liver histology and health related quality of life, as well as a reduced risk of HCC and liver-related mortality (27-30). The degree of response depends on a variety of factors and these may also differ in various patient populations (31). Viral genotype, viral load, patient age, BMI, race, environment and several other factors have been shown to correlate with SVR (32-34).

Despite that the PEG-RBV has become a standard treatment of HCV around the world (35) and in Iran too (36), but in developing countries like Iran, INF-RBV is still used for treating HCV, due to the high cost of treatment with PEG-RBV (37, 38). Therefore,, the main purpose of this study was to evaluate the outcomes based on genotype in the both of treatment.

Patients and Methods

All data for this cross-sectional study were collected from medical records of 77 naïve patients with chronic hepatitis C, who were referred to private gastroenterology clinics between years 2007 through 2009 in Tehran. The selected patients had chronic hepatitis C, evidenced by a liver biopsy. A sample of 77 naïve HCV patients with a minimum age of 17 was selected.

Exclusion criteria included simultaneous infection with hepatitis B or HIV, active liver disease, and existence of liver disease with a cause other than hepatitis C, HCC, liver transplantation history, uncontrolled diabetes mellitus, sever cardiac or pulmonary disease, autoimmune disorders, retinopathy, severe depression, uncontrolled psychotic disorders and existing drug addiction.

A checklist was designed to gather information from medical records of HCV patients, which includes age, gender, marital status, HCV genotype, HCV risk factors, the type of combination treatment and the duration of treatment. Patients had participated in this study taking two types of combination therapies. One was conventional interferon (Roche® Products Ltd, Switzerland) and ribavirin (Copegus®, Roche) and another was peg-interferon α -2a (Pegasys®, Roche, Switzerland) and ribavirin (Copegus®, Roche), based on standard protocol of the Iranian Ministry of health. This protocol consisted of conventional interferon (3 MU three times a week) plus ribavirin (800-1200 mg per day) was for 24 weeks (genotypes 2, 3) or 48 weeks (genotype 1 and 4). Also, peg-interferon α -2a in a fixed dose of 180 micrograms per week plus ribavirin (800-1200 mg per day) was for 24 (genotypes 2, 3) or 48 weeks (genotype 1 and 4). In addition, patients were followed up to six months after the intervention for complications of the rate of SVR.

Outcome Measurement

The HCV RNA was measured at the outset of the treatment, in weeks 12, 24, 48 and also six months after the end of treatment. The main outcome was SVR level, which is defined as no virus present (undetectable HCV RNA) in a blood sample 6 months after completion of therapy.

The secondary outcomes included; early viral response (EVR), as undetectable HCV RNA or a decrease of more than 2 logs IU compared to the level at 12th week of the treatment and the end of treatment response (ETR), and undetectable HCV RNA at the end of treatment. On the basis of the obtained outcomes, patients were divided into four groups; non-responder patients with no EVR, relapse patients with ETR but without SVR, patients who had SVR and patients who had lost follow-up their treatment because of side effects of the medications such as; fatigue, muscle aches, depression, headache, flu like, fever, itching, GI symptoms, hair loss, rash, insomnia and dry skin.

Statistical analysis

Data analysis was performed using statistical package for social sciences (SPSS) 16.0 software (SPSS Inc., Chicago, IL, USA). Descriptive statistics and frequency distribution such as mean, standard deviation and percentage were employed. A chi-square test was used to compare the qualitative variables. $P < 0.05$ was considered as statistically significant.

Results

In total, seventy-seven naïve patients with chronic HCV were enrolled in this study out of which 58 (75.3%) were male. The mean age was 49.1 ± 10.2 (\pm standard deviation) years. Majority of patients 68 (88.3%) were married. Intravenous drug user (IVDU) and blood transfusion were the commonest risk factors for HCV. In terms of history, 6 (7.8%) patients were IVDU and 4 (5.2%) patients had blood transfusion. The most common virus genotype was 1a (61%). All the patients were treatment-naïve. Table 1 shows patients characteristics at the outset of the study. In terms of outcome in 43 chronic HCV patients who were treated with INF-RBV results showed; 5 patients (11.6%) suffered from a relapse, 7 patients (16.3%) did lost follow-up with their treatment, 15 patients

(34.9%) were non-responders and 16 patients (37.2%) had reached SVR. Outcomes in 34 chronic HCV patients who treated with PEG-RBV are as follows: one patient (2.9%) was non-responder, 5 patients (14.7%) did lost follow-up with their treatment, 5 patients (14.7%) suffered from a relapse and 23 patients (67.6%) had reached SVR. Table 2 shows antiviral treatment outcomes in HCV patients based on genotype.

Table1. Basic characteristic of patients (n=77)

Patients characteristics	No (%)
Male	58(75.3)
Female	19(24.7)
Age, y, mean \pm SD	49.1 \pm 10.2
Age range	21-78
Marital status	
Single	9(11.7)
Married	68(88.3)
Genotype	
1a	47(61)
1b	11(14.3)
3a	19(24.7)
HCV risk factors	
IVDU	6(7.8)
Blood transfusion	4(5.2)
Needle stick	3(3.9)

Abbreviation: IVDU, Intravenous drug user

The chance of achieving SVR in patients who had been treated with PEG-RBV was more than those treated with INF-RBV (OR=3.528, CI95 %=1.367-9.105) (Table 3). Treatment with PEG-RIB, the overall SVR is 67.6%, compared with a rate between 37.2% with INF-RIB ($P < 0.05$). According to the results of this table, we did not reach statistical significance differences between achieving SVR and different genotypes in INF-RBV (table 3).

Table 4 shows the outcomes of re-treatment of HCV patients who not achieved SVR in the first course of treatment. As it is seen, SVR mostly occurs in patients who were non-responder because many patients (34.9%) have not responded to therapy with INF-RBV. So in re-treating, they treated with PEG-RIB instead of INF-RBV and 8 patients (61.5%) from 13 patients sustained SVR. Also, finally the

Table 2. Treatment outcomes based on genotype

Treatment	Genotype	SVR	Lost follow-up	Relapse	Non-responder	Total
INF-RBV	1a	10 (23.3)	5 (11.6)	3 (7)	9 (20.9)	27 (62.8)
	1b	4 (9.3)	0	1(2.3)	3 (7)	8 (18.6)
	3a	2 (4.7)	2(4.7)	1 (2.3)	3 (7)	8 (18.6)
	Total	16 (37.2)	7 (16.3)	5 (11.6)	15 (34.9)	43 (100)
PEG-RIBV	1a	13(38.2)	4 (11.8)	3 (8.8)	0	20 (58.8)
	1b	2 (5.9)	1 (2.9)	0	0	3 (8.8)
	3a	8 (23.5)	0	2 (5.9)	1 (2.9)	11 (32.4)
	Total	23 (67.6)	5 (14.7)	5 (14.7)	1 (2.9)	34 (100)
Total		39 (50.6)	12 (15.5)	10 (12.9)	16 (20.7)	77 (100)

Abbreviation: SVR, Sustained Virological Response; INF-RBV, Interferon and Ribavirin; PEG-RIBV, Peg-interferon and ribavirin

Table 3. Multivariate Analysis results between patients with and without Sustain Virological Response (SVR)

Treatment	Genotype	SVR	Non-SVR	P-value	OR	95% CI for OR
INF-RIB	1a	10(37.0)	17(63.0)	0.372*	1	-
	1b	4(50.0)	4(50.0)		4	0.416-38.454
	3a	2(25.0)	6 (75.0)		0.8	0.191-3.347
PEG-RIB	1a	13(65.0)	7(35.0)	0.906*	1	-
	1b	2(66.7)	1(33.3)		0.714	0.063-8.150
	3a	8(72.7)	3(27.3)		1.286	0.237-6.963
INF-RIB		16(37.2)	27(62.8)	0.008*	1	-
PEG-RIB		23(67.6)	11(32.4)		3.528	1.367-9.105

Abbreviation: SVR, Sustained Virological Response; OR, odds ratio. *chi square test, $P < 0.05$ was considered as statistically significant

percent of patients who achieved SVR in re-treatment was (46.16%).

Table 4. Re-treatment outcomes

	SVR*	Non SVR	Total
	N (%)	N (%)	N (%)
Non-responder	8(61.5)	5(38.5)	13(100)
Relapse	4(50)	4(50)	8 (100)
Lost follow-up	0	5(100)	5 (100)
Total	12(46.1)	14(53.8)	26(100)

* SVR: Sustained virological response

Discussion

The findings of the present study show the rate of SVR in patients who treated with PEG-RBV was (67.6%) and these rates were different among the various genotypes. The highest SVR was observed in patients with genotype 3a, while the lowest SVR was identified in patients with genotype 1a is treated with PEG-RBV. In addition, the chance of achieving SVR in patients

who had been treated with PEG-RBV was more than those treated with INF-RBV (OR=3.528, CI95 % =1.367-9.105). Also, the chance of attaining SVR is higher among the patients with genotype 3a than among those with other genotypes (OR=1.286, CI95 % =0.237-6.963). However, in patients treated with INF-RBV the rate of SVR in genotype 3a was lower than genotype 1a and 1b. One might assume that the number of patients with genotype 3a was very lower than other genotypes in INF-RBV. Therefore, we did not reach statistical significance differences between achieving SVR and different genotypes in INF-RBV.

Overall, the results of this study confirms other studies, which showed the use of PEG-RBV instead of INF-RBV in treatment of HCV patients leads to improved treatment outcomes in these patients with ETR and SVR rates increasing to 69% and 56% respectively in different genotypes (21, 39, 40). Genotypes has been the most important predictors in a variety of studies (32,

41). In comparison to other genotypes, genotype 1 has been associated with lower SVR (15, 16, 22). Also in this study, genotype 1 in PEG-RBV therapy had low SVR.

Despite all of these studies about the efficacy and safety of treatment with PEG-RBV, in developing countries like Iran, INF-RBV is still used for treating HCV. Use of this treatment just because it has a low cost than PEG-RBV (4,403 PPP\$ vs. 20,010 PPP\$) (37). However, the SVR rate is very low in this treatment, especially in genotype 1 that is known as difficult to treat. Another problem is the side effects of interferon than the peg-interferon (19). Therefore, many patients are not able to tolerate these side effects and thus leave their treatment (as called as lost follow-up in this study). As the results of this study indicated that most people who left their treatment was treated with INF-RBV (16.3%).

In general, reaching an SVR in patients with a prior history of treatment has been reported to be 20-30% (42). In the study by Alavian et al. SVR in naïve patients was found to be 62.9% and in non-responder or relapsing patients it was found to be 35.3% (43) and the study by Namazee et al. showed an SVR proportion of 56%, 60% and 28% in naïve, relapse and non-responder patients using conventional interferon, respectively (44). Our study showed an SVR proportion in naïve patients is 67.6%, 37.2% using PEG-RBV and INF-RBV, respectively. Our study also showed the SVR rate in re-treatment is 61.5% in non-responder and 50% in relapsing patients. The most non-responder in this study at first were treated with INF-RBV and then re-treated with PEG-RBV and they achieved SVR.

The primary goal of re-treatment was to achieve an SVR. Secondary goals include the prevention of progressive histologic diseases, the regression of fibrosis, a decrease in the risk of HCC, and potentially a reduction in the risk of hepatic decomposition. According to other studies; The SVR in INF-RBV non-responders re-treated

with PEG-RBV between 4% and 12%. Unfortunately, re-treatment options are limited, and their efficacy is low (42, 45, 46).

Despite improvements in antiviral therapy in recent years, the treatment of chronic hepatitis C is still a challenging endeavor requiring significant improvement, especially in developing countries like Iran.

Acknowledgements

The project was completely supported and funded by Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences.

References

1. Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. *Liver Transpl* 2003;9:S10-13.
2. Alter MJ. Epidemiology of hepatitis C virus infection. *World J Gastroenterol* 2007;13:2436-41.
3. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. *J Hepatol* 2008;48:148-62.
4. Alavian SM. Hepatitis C infection in Iran; A review article. *Iran J Clin Infect Dis* 2009;4:47-59.
5. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. *J Hepatol* 2001; 33:455-63.
6. Hoofnagle JH. Course and outcome of hepatitis C. *J Hepatol* 2002;36:S21-29.
7. Williams R. Global challenges in liver disease. *J Hepatol* 2006;44:521-26.
8. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. *Arch Iran Med* 2005;8:84-90.
9. El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. *Eur J Health Econ* 2005;6:159-65.
10. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. *J Hepatol* 1997;26:34S-8S.

11. H. T. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. *J Gastroenterol* 1997;112:1017-21.
12. Carithers RL Jr, SS. E. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. *J Hepatol* 1997;26:83S-8S.
13. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *N Engl J Med* 1989;321:1506-10.
14. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Jr., Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. *N Engl J Med* 1989;321:1501-506.
15. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 1998;352:1426-32.
16. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998;339:1485-92.
17. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnernborg A. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. *Lancet* 1998;351:83-87.
18. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. *J Gastroenterol* 2006;130:225-30.
19. Kim AI, Saab S. Treatment of hepatitis C. *Am J Med* 2005;118:808-15.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. *J Hepatol* 2009;49:1335-74.
21. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975-82.
22. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004;140:346-55.
23. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. *J Hepatol* 2005;43:250-57.
24. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. *AIDS research and human retroviruses* 2007;23:972-82.
25. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med* 2004 29;351:438-50.
26. Alavian SM. Management of Hepatitis C Infection: Regional Guideline. *Hepat Mon* 2004;4:1-10.
27. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfectd with human immunodeficiency virus and hepatitis C virus. *J Hepatol* 2009;50:407-13.
28. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. *J Hepatol* 2009;49:729-38.
29. Breitenstein S, Dimitroulis D, Petrowsky H, Puhon MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. *Br J Surg* 2009;96:975-81.
30. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. *Clin Gastroenterol Hepatol* 2010;8:192-99.
31. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. *N Engl J Med* 2004;350:2265-71.

32. Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. *Ann Saudi Med* 2009;29:4-14.
33. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. *Liver Int* 2010;30:1173-80.
34. Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. *J Clin Gastroenterol* 2010;44:140-45.
35. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. *J Hepatol* 2002;36:S3-20.
36. Alavian SM, Mirmomen S, Lankarani KB, Adibi P, S. M. What is the optimal treatment? *Hepat Mon* 2004;4:1-10.
37. Ashtari S, Vahedi M, Pourhoseingholi MA, Karkhane M, Kimii A Z, Pourhoseingholi A, et al. Direct medical care costs associated with patients diagnosed with chronic HCV. *Hepat Mon* 2013; 13:e8415.
38. Ashtari S, Vahedi M, Pourhoseingholi MA, Pourhoseingholi A, Safaee A, Moghimi-Dehkordi B, et al. Estimation of average diagnosis and treatment costs of hepatitis C. *Gastroenterol Hepatol Bed Bench* 2012;5:139-45.
39. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. *N Engl J Med* 2009;361:580-93.
40. Jacobson IM, Brown RS, Jr., Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. *J Hepatol* 2007;46:971-81.
41. Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. *Antivir Ther* 2009;14:45-54.
42. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. *J Gastroenterol* 2004;126:1015-23.
43. Alavian SM, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh AK. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. *Hepat Mon* 2004;4:53-58.
44. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. *Hepat Mon* 2012;12:e6151.
45. Moskovitz DN, Manoharan P, Heathcote EJ. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. *Can J Gastroenterol* 2003;17:479-82.
46. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC, Jr., et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. *Am J Gastroenterol* 2005;100:2453-62.